Axcella Health - AXLA Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price targets for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they predict the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price.
View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts.

Axcella Health's stock was trading at $0.3275 at the beginning of the year. Since then, AXLA stock has increased by 108.4% and is now trading at $0.6825.
View the best growth stocks for 2023 here.

Axcella Health saw a decline in short interest in January. As of January 15th, there was short interest totaling 190,000 shares, a decline of 44.2% from the December 31st total of 340,600 shares. Based on an average daily trading volume, of 1,090,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the company's stock are sold short.
View Axcella Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AXLA earnings forecast.

Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.04.

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

(AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Axcella Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane, Ventures Fund Iv LP Flagship and William Hinshaw.
View institutional ownership trends.

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXLA stock can currently be purchased for approximately $0.68.

Axcella Health (NASDAQ:AXLA) has a market capitalization of $50.20 million. The company earns $-64,630,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.